Want to see SCYX full AI Analyst Report?
SCYNEXIS (SCYX) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ibrexafungerp | Vulvovaginal Candidiasis, Vaginal Candidiasis, Candida Infection | Phase I | Completed | Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp | Jan 09, 2024 | ― |
| Ibrexafungerp | Fungal Disease | Phase I | Completed | ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects | Dec 08, 2022 | ― |
| Ibrexafungerp | Vulvovaginal Candidiasis | Phase III | Completed | Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis | May 23, 2022 | ― |
| Fluconazole, Scy-078, Echinocandin | Candidemia, Candidiasis, Invasive | Phase III | Recruiting | A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole | Dec 16, 2021 | ― |
| [14C]-Ibrexafungerp | Fungal Infection | Phase I | Completed | ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects | Mar 04, 2020 | ― |
| Pra, Scy-078 Plus Pra | Pharmacokinetics | Phase I | Completed | Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects | Sep 10, 2019 | ― |
| Dab, Scy-078 Plus Dab | Pharmacokinetics | Phase I | Completed | Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects | Sep 03, 2019 | ― |
| Fluconazole Tablet, Ibrexafungerp | Recurrent Vulvovaginal Candidiasis | Phase III | Completed | Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) | Jul 19, 2019 | ― |
| Ibrexafungerp | Candida Vulvovaginitis | Phase III | Completed | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis | Jun 12, 2019 | ― |
| Ibrexafungerp | Candida Vulvovaginitis | Phase III | Completed | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303) | Oct 30, 2018 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ibrexafungerp | Phase I | Vulvovaginal Candidiasis, Vaginal Candidiasis, Candida Infection | Completed | Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp | Jan 09, 2024 | ― |
| Ibrexafungerp | Phase I | Fungal Disease | Completed | ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects | Dec 08, 2022 | ― |
| Ibrexafungerp | Phase III | Vulvovaginal Candidiasis | Completed | Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis | May 23, 2022 | ― |
| Fluconazole, Scy-078, Echinocandin | Phase III | Candidemia, Candidiasis, Invasive | Recruiting | A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole | Dec 16, 2021 | ― |
| [14C]-Ibrexafungerp | Phase I | Fungal Infection | Completed | ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects | Mar 04, 2020 | ― |
| Pra, Scy-078 Plus Pra | Phase I | Pharmacokinetics | Completed | Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects | Sep 10, 2019 | ― |
| Dab, Scy-078 Plus Dab | Phase I | Pharmacokinetics | Completed | Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects | Sep 03, 2019 | ― |
| Fluconazole Tablet, Ibrexafungerp | Phase III | Recurrent Vulvovaginal Candidiasis | Completed | Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) | Jul 19, 2019 | ― |
| Ibrexafungerp | Phase III | Candida Vulvovaginitis | Completed | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis | Jun 12, 2019 | ― |
| Ibrexafungerp | Phase III | Candida Vulvovaginitis | Completed | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303) | Oct 30, 2018 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does SCYNEXIS Inc (SCYX) have in its pipeline
SCYNEXIS SCYX is currently developing the following drugs: Ibrexafungerp, Fluconazole, Scy-078, Echinocandin, [14C]-Ibrexafungerp, Pra, Scy-078 Plus Pra, Dab, Scy-078 Plus Dab, Fluconazole Tablet, Ibrexafungerp, Voriconazole, Scy-078, Scy-078, Fluconazole, Scy-078, Fluconazole, Scy-078, Micafungin, Scy-635, Pegasys, Copegus. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
